SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG Stops Tasigna Trial in Patients with GIST

April 11, 2011 | 
1 min read
ZURICH, April 11 (Reuters) - Novartis AG (NOVN.VX) has stopped a late-stage trial for Tasigna in intestinal tumors after a committee said the cancer drug was unlikely to show it was more effective than Glivec, the current standard of care.
Clinical research Phase III
Novartis
MORE ON THIS TOPIC
Focal seizure. Vector illustration of human brain and electroencephalograhy or EEG originating from temporal lobe.
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Layoffs
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees
September 11, 2025
 · 
1 min read
 · 
Tristan Manalac
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Immunology and inflammation
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
September 10, 2025
 · 
2 min read
 · 
Tristan Manalac